title: Usefulness of imaging-guided catheter drainage and talc sclerotherapy in patients with metastatic gynecologic malignancies and symptomatic pleural effusions.
abstract: OBJECTIVE
  The purpose of our study was to assess the usefulness of imaging-guided catheter drainage and talc sclerotherapy in patients with metastatic gynecologic malignancies and symptomatic pleural effusions and to assess the affect of ascites on the success rate of this treatment.
  
  
  METHODS
  Twenty-five patients (mean age, 63 years) with metastatic gynecologic malignancies who had 26 symptomatic effusions treated at our institution over a 4-year period with imaging-guided catheter drainage and talc sclerotherapy were included in this study. Response to treatment was assessed by comparing pre-, immediate post-, and 30-day postsclerotherapy chest radiographs. Response to the treatment was graded as complete (no reaccumulation), partial (accumulation above immediate post- but below presclerotherapy level), or no response (reaccumulation to or above the presclerotherapy level). The presence of ascites on CT (n = 23), sonography (n = 1), direct intraoperative visualization (n = 1), or at physical examination (n = 1) was also noted.
  
  
  RESULTS
  Of the 25 patients, 13 patients with 14 treated malignant effusions survived at least 30 days after sclerotherapy and formed the final study group. The remaining patients either died (n = 11) or were lost to follow-up (n = 1). At 30 days, 12 of the 14 treated effusions showed complete responses and one showed a partial response. The overall response rate was 86%. Abdominal ascites was present at the time of treatment in 11 patients (79%) and did not affect the success rate (p > 0.999).
  
  
  CONCLUSIONS
  Imaging-guided catheter drainage and talc sclerotherapy are an effective treatment for symptomatic pleural effusions in patients with metastatic gynecologic malignancies. Ascites does not adversely affect the response to pleurodesis.
authors.affiliation: Department of Radiology, Duke University Medical Center, Box 3808, Durham, NC 27710, USA.
authors.forename: Edith M
authors.initials: EM
authors.lastname: Marom
authors.forename: Jeremy J
authors.initials: JJ
authors.lastname: Erasmus
authors.forename: James E
authors.initials: JE
authors.lastname: Herndon
authors.forename: Chunfeng
authors.initials: C
authors.lastname: Zhang
authors.forename: H Page
authors.initials: HP
authors.lastname: McAdams
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001201:Ascites / Q000401:mortality*; D002277:Carcinoma / Q000401:mortality / Q000556:secondary* / Q000628:therapy*; D002404:Catheterization; D004322:Drainage; D005260:Female; D005500:Follow-Up Studies; D005833:Genital Neoplasms, Female / Q000401:mortality / Q000556:secondary* / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D016066:Pleural Effusion, Malignant / Q000401:mortality* / Q000628:therapy*; D012597:Sclerosing Solutions / Q000627:therapeutic use*; D015911:Sclerotherapy; D025321:Surgery, Computer-Assisted; D015996:Survival Rate; D013627:Talc / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D012597:Sclerosing Solutions; D013627:Talc